Journal
NANOTECHNOLOGY
Volume 24, Issue 29, Pages -Publisher
IOP PUBLISHING LTD
DOI: 10.1088/0957-4484/24/29/295102
Keywords
-
Funding
- March of Dimes
- NIH (NIA) [R21 AG30321]
- NIH (NIBIB) [R01 EB04537]
- Burroughs Wellcome Foundation
- NIH [T90 DA22873, T32 HL069765, F32 AI080117, P30 DK058404, P30 CA68485]
- Vanderbilt University through an Innovation and Discovery in Engineering and Science (IDEAS) award
Ask authors/readers for more resources
Respiratory syncytial virus (RSV) is a major cause of pneumonia and wheezing in infants and the elderly, but to date there is no licensed vaccine. We developed a gold nanorod construct that displayed the major protective antigen of the virus, the fusion protein (F). Nanorods conjugated to RSV F were formulated as a candidate vaccine preparation by covalent attachment of viral protein using a layer-by-layer approach. In vitro studies using ELISA, electron microscopy and circular dichroism revealed that conformation-dependent epitopes were maintained during conjugation, and transmission electron microscopy studies showed that a dispersed population of particles could be achieved. Human dendritic cells treated with the vaccine induced immune responses in primary human T cells. These results suggest that this vaccine approach may be a potent method for immunizing against viruses such as RSV with surface glycoproteins that are targets for the human immune response.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available